Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent

Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management o...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology in drug development Vol. 13; no. 1; pp. 111 - 116
Main Authors Pai, Sudhakar M., Yamada, Hiroyuki
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
AbstractList Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat C and AUC reductions were 53% and 45%, respectively. For Treatment C, C and AUC reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat Cmax and AUCinf reductions were 53% and 45%, respectively. For Treatment C, Cmax and AUCinf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non‐calcium‐based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open‐label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A). With coadministration of the 2 drugs (Treatment B), enarodustat C max and AUC inf reductions were 53% and 45%, respectively. For Treatment C, C max and AUC inf reductions were 11% and 6%, respectively, and for Treatment D the corresponding values were 8% and 20%. Thus, coadministration of enarodustat and sevelamer carbonate resulted in a substantial reduction (≈50%) in the oral bioavailability of enarodustat. However, the interaction was substantially mitigated by staggering the administration of enarodustat and sevelamer carbonate. Administration of 4 single oral doses of enarodustat 25 mg, with or without sevelamer carbonate, were safe and well tolerated in this study.
Author Pai, Sudhakar M.
Yamada, Hiroyuki
Author_xml – sequence: 1
  givenname: Sudhakar M.
  surname: Pai
  fullname: Pai, Sudhakar M.
  email: pai@akrospharma.com
  organization: Akros Pharma Inc
– sequence: 2
  givenname: Hiroyuki
  surname: Yamada
  fullname: Yamada, Hiroyuki
  organization: Pharmaceutical Division, Japan Tobacco Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37975611$$D View this record in MEDLINE/PubMed
BookMark eNp10U9LHDEUAPBQLPVPPfQLlEAvFbqaTHaTyVHXrRUEBVvoLWQyL25kJhmTjGWv_eTNuOqhYC554f3yeLy3j3Z88IDQJ0qOKSHViRna9pgyxt-hvYpyMhN8Xu-8xuz3LjpM6Z6UwwmldP4B7TIhxYJTuof-rqwFk3GwOK8B36xDGtY6Az5zvoWIb-EROt2XaKljE_yUCv7JnrmgH7XrdOM6lzdTiZXXMbRjyjp_w9rj66g7vIqbvI5hCA6SS_g2u37sdHb-Dp_egc8f0XuruwSHz_cB-vV99XP5Y3Z1fXG5PL2aGUYZn2lrqJGMLmrRCFvThrW6sSXTsIUVurKVZUDAtIYKIS1IXdVGzjlv6qq8K3aAvm7rDjE8jJCy6l0y0HXaQxiTqmpJy1QIl4V--Y_ehzH60p2qJCn1hOTzoj4_q7HpoVVDdL2OG_Uy3QKOtsDEkFIE-0ooUdPy1LQ8NS2v2JOt_eM62LwN1fLm_Pzpxz-lW5uH
Cites_doi 10.1002/cpdd.1252
10.1002/cpdd.923
10.1177/00912700122009872
10.1002/cpdd.1263
10.1002/cpdd.933
10.1016/j.semnephrol.2006.06.001
10.1345/aph.1M291
10.1093/ndt/gfv182.06
10.1111/1744-9987.13820
10.1093/ndt/gfi020
10.1053/j.ajkd.2003.08.027
10.1159/000517053
10.1111/1744-9987.13724
10.1093/ndt/gfh446
10.2165/00003495-200868010-00006
10.1093/ndt/gfm316
10.1159/000500487
10.1016/j.jchromb.2021.122754
10.1002/cpdd.752
10.1021/acsmedchemlett.7b00404
10.1159/000496929
10.1016/j.ekir.2021.04.037
ContentType Journal Article
Copyright 2023, The American College of Clinical Pharmacology.
American College of Clinical Pharmacology.
Copyright_xml – notice: 2023, The American College of Clinical Pharmacology.
– notice: American College of Clinical Pharmacology.
DBID AAYXX
CITATION
NPM
K9.
7X8
DOI 10.1002/cpdd.1336
DatabaseName CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2160-7648
EndPage 116
ExternalDocumentID 37975611
10_1002_cpdd_1336
CPDD1336
Genre article
Journal Article
GroupedDBID -MK
05W
0R~
1OC
33P
3SF
52U
52V
53G
8-1
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AAXRX
AAYCA
AAZKR
ABCUV
ABDBF
ABJNI
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACRPL
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BNHUX
BOGZA
BRXPI
C45
DCZOG
DPXWK
DRFUL
DRMAN
DRSTM
EBS
EJD
FUBAC
G-S
GODZA
H13
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LSO
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
O66
O9-
OVD
P2W
PQQKQ
R.K
ROL
SUPJJ
TEORI
TUS
WBKPD
WIH
WIJ
WIK
WOHZO
WOIKV
WPGGZ
WXSBR
WYJ
ZZTAW
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
K9.
7X8
ID FETCH-LOGICAL-c3136-afc1c931587b7f81b3dabf136b35f7a2f2f3e0ecdc1779fe9a28c9466b8279f23
ISSN 2160-763X
2160-7648
IngestDate Fri Jul 11 15:38:02 EDT 2025
Tue Aug 12 12:51:03 EDT 2025
Mon Jul 21 05:54:07 EDT 2025
Tue Jul 01 00:19:15 EDT 2025
Wed Jan 22 16:15:47 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ESRD
HIF-PH
sevelamer carbonate
JTZ-951
enarodustat
DDI
pharmacokinetics
clinical pharmacology
CKD
Language English
License 2023, The American College of Clinical Pharmacology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3136-afc1c931587b7f81b3dabf136b35f7a2f2f3e0ecdc1779fe9a28c9466b8279f23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 37975611
PQID 2908277964
PQPubID 2034576
PageCount 6
ParticipantIDs proquest_miscellaneous_2891756069
proquest_journals_2908277964
pubmed_primary_37975611
crossref_primary_10_1002_cpdd_1336
wiley_primary_10_1002_cpdd_1336_CPDD1336
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2024
2024-01-00
2024-Jan
20240101
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: January 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle Clinical pharmacology in drug development
PublicationTitleAlternate Clin Pharmacol Drug Dev
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 44
2021; 1176
2021; 7
2017; 8
2021; 6
2021; 10
2023; 12
2004; 19
2015; 30
2006; 26
2020; 9
2019; 49
2005; 20
2022; 26
2008; 68
2007; 22
2003; 42
2001; 41
2019; 143
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_10_1
e_1_2_8_21_1
e_1_2_8_11_1
e_1_2_8_22_1
e_1_2_8_12_1
e_1_2_8_23_1
References_xml – volume: 26
  start-page: 261
  issue: 4
  year: 2006
  end-page: 268
  article-title: Pathogenesis of renal anemia
  publication-title: Semin Nephrol
– volume: 8
  start-page: 1320
  year: 2017
  end-page: 1325
  article-title: Discovery of JTZ‐951: a HIF prolyl hydroxylase inhibitor for the treatment of renal anemia
  publication-title: ACS Med Chem Lett
– volume: 26
  start-page: 345
  issue: 2
  year: 2022
  end-page: 356
  article-title: Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
  publication-title: Ther Apher Dial
– volume: 10
  start-page: 884
  issue: 8
  year: 2021
  end-page: 898
  article-title: Thorough QT/QTc evaluation of the cardiac safety of enarodustat (JTZ‐951), an oral erythropoiesis‐stimulating agent, in healthy adults
  publication-title: Clin Pharmacol Drug Dev
– volume: 6
  start-page: 1840
  issue: 7
  year: 2021
  end-page: 1849
  article-title: A Phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study
  publication-title: Kidney Int Rep
– volume: 20
  start-page: 2288
  issue: 10
  year: 2005
  end-page: 2289
  article-title: Drug interaction between sevelamer and furosemide
  publication-title: Nephrol Dial Transplant
– volume: 12
  start-page: 683
  issue: 7
  year: 2023
  end-page: 690
  article-title: Pharmacokinetics of enarodustat in non‐Japanese and Japanese healthy subjects and in patients with end‐stage renal disease on hemodialysis
  publication-title: Clin Pharmacol Drug Dev
– volume: 41
  start-page: 193
  issue: 2
  year: 2001
  end-page: 198
  article-title: Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate‐binding polymer, does not interfere with digoxin or warfarin pharmacokinetics
  publication-title: J Clin Pharmacol
– volume: 1176
  year: 2021
  article-title: A highly sensitive and selective UPLC‐MS/MS assay for the determination of enarodustat (JTZ‐951) in human plasma
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci
– volume: 49
  start-page: 165
  issue: 2
  year: 2019
  end-page: 174
  article-title: A placebo‐controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long‐term trial
  publication-title: Am J Nephrol
– volume: 68
  start-page: 85
  issue: 1
  year: 2008
  end-page: 104
  article-title: Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end‐stage renal disease on haemodialysis
  publication-title: Drugs
– volume: 26
  start-page: 679
  issue: 4
  year: 2022
  end-page: 693
  article-title: Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: a review of the evidence
  publication-title: Ther Apher Dial
– volume: 42
  start-page: 1253
  issue: 6
  year: 2003
  end-page: 1259
  article-title: Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin
  publication-title: Am J Kidney Dis.
– volume: 10
  start-page: 463
  issue: 5
  year: 2021
  end-page: 470
  article-title: Hemodialysis clearance of enarodustat (JTZ‐951), an oral erythropoiesis stimulating agent, in patients with end‐stage renal disease
  publication-title: Clin Pharmacol Drug Dev
– volume: 19
  start-page: 2630
  issue: 10
  year: 2004
  end-page: 2633
  article-title: The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation
  publication-title: Nephrol Dial Transplant
– volume: 9
  start-page: 728
  issue: 6
  year: 2020
  end-page: 741
  article-title: A mass balance study of C‐labeled JTZ‐951 (enarodustat), a novel orally available erythropoiesis‐stimulating agent, in patients with end‐stage renal disease on hemodialysis
  publication-title: Clin Pharmacol Drug Dev
– volume: 12
  start-page: 667
  issue: 7
  year: 2023
  end-page: 682
  article-title: Evaluation of drug–drug interaction potential of enarodustat (JTZ‐951) using a cytochrome P450 probe cocktail
  publication-title: Clin Pharmacol Drug Dev
– volume: 22
  start-page: 2900
  year: 2007
  end-page: 2908
  article-title: Serum erythropoietin concentrations and responses to anemia in patients with or without kidney disease
  publication-title: Nephrol Dial Transplant
– volume: 44
  start-page: 127
  issue: 1
  year: 2010
  end-page: 134
  article-title: Sevelamer carbonate
  publication-title: Ann Pharmacother
– volume: 30
  start-page: iii293
  issue: 3
  year: 2015
  end-page: iii294
  article-title: JTZ‐951, a novel HIF‐PHD inhibitor, demonstrates increases in hemoglobin, iron mobilization, reproducible pharmacokinetics, and safety following once daily administration for 15 days in patients with anemia receiving hemodialysis
  publication-title: Nephrol Dial Transplant
– volume: 143
  start-page: 77
  issue: 2
  year: 2019
  end-page: 85
  article-title: Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo‐controlled Phase 2b trial followed by long‐term trial
  publication-title: Nephron
– volume: 7
  start-page: 494
  issue: 6
  year: 2021
  end-page: 502
  article-title: A Phase 3 study of enarodustat (JTZ‐951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study
  publication-title: Kidney Dis (Basel)
– ident: e_1_2_8_15_1
  doi: 10.1002/cpdd.1252
– ident: e_1_2_8_12_1
  doi: 10.1002/cpdd.923
– ident: e_1_2_8_21_1
  doi: 10.1177/00912700122009872
– ident: e_1_2_8_14_1
  doi: 10.1002/cpdd.1263
– ident: e_1_2_8_11_1
  doi: 10.1002/cpdd.933
– ident: e_1_2_8_3_1
  doi: 10.1016/j.semnephrol.2006.06.001
– ident: e_1_2_8_16_1
  doi: 10.1345/aph.1M291
– ident: e_1_2_8_22_1
  doi: 10.1093/ndt/gfv182.06
– ident: e_1_2_8_5_1
  doi: 10.1111/1744-9987.13820
– ident: e_1_2_8_20_1
  doi: 10.1093/ndt/gfi020
– ident: e_1_2_8_18_1
  doi: 10.1053/j.ajkd.2003.08.027
– ident: e_1_2_8_9_1
  doi: 10.1159/000517053
– ident: e_1_2_8_10_1
  doi: 10.1111/1744-9987.13724
– ident: e_1_2_8_19_1
  doi: 10.1093/ndt/gfh446
– ident: e_1_2_8_17_1
  doi: 10.2165/00003495-200868010-00006
– ident: e_1_2_8_2_1
  doi: 10.1093/ndt/gfm316
– ident: e_1_2_8_8_1
  doi: 10.1159/000500487
– ident: e_1_2_8_23_1
  doi: 10.1016/j.jchromb.2021.122754
– ident: e_1_2_8_13_1
  doi: 10.1002/cpdd.752
– ident: e_1_2_8_4_1
  doi: 10.1021/acsmedchemlett.7b00404
– ident: e_1_2_8_6_1
  doi: 10.1159/000496929
– ident: e_1_2_8_7_1
  doi: 10.1016/j.ekir.2021.04.037
SSID ssj0000601114
Score 2.266519
Snippet Enarodustat is an orally available hypoxia‐inducible factor‐prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in...
Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 111
SubjectTerms Bioavailability
CKD
clinical pharmacology
DDI
enarodustat
ESRD
HIF‐PH
JTZ‐951
pharmacokinetics
sevelamer carbonate
Title Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.1336
https://www.ncbi.nlm.nih.gov/pubmed/37975611
https://www.proquest.com/docview/2908277964
https://www.proquest.com/docview/2891756069
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVbCqMvY9_L1g1tjDJo3NpSHNmPzUcJg22BpdA3I0tyE7rYwYkL2eN--a4k23GWFba9GMVSJPA5vr5X0j1C6EPIvNh3XekIzqQDX2jlcOH6jhB-V4S-jGmgs5E_f-mNL7ufrvyr7YS-yS5Zx6fixx_zSv4HVbgHuOos2X9Atu4UbkAZ8IUrIAzXv8K4lB4ul_kns2y1nIHveNLXGog52IFbBYBDacDzWE-Tq3JtQB9ByW_5_LtV6Tar7KOUa_VXnWFkt3SefNXJ-6N8Y49SgJB6vgLndL4wJ37p2ZTratdMJXVQpVkut4LYJq9Q5sV1lZ_V3GozsYdhfyvkjN9oRaHaCPEFl8avHc_zbFPczJvTE6TbmJ5QxowRr-c6rGf1NGubS_e4ZQ1oaXr3DLsVihVLKU8hqu412wAmy4VBmLKQgT_obb9t9Y7Dquo-OiAQUJAWOjjvD_sX9Xyc1qWB2LASn3LJWT3YIXpQ_X3Xe9kLSXYjHOOiTB-hh2Vsgc8tUR6jeyp9go4nFotNB0-3uXarDj7GkwZKT9FPyyacJRgYgms2YcsmXLMJ12zCWWra_sYm3UWDTR3MU6y5hHe5hBtcwoZLz9DlxWg6GDvlCR2OoB7tOTwRngip5wcsZglEQFTyOIGamPoJ4yQhCVWuElJ4jIWJCjkJhD7RIA4I_Cb0OWqlWapeItxNpOIeh29vV0A5DiQEusQVkio_hKCjjd5XTz5aWiGWyEpuk0gjFWmk2uiowiQq39NVREJwc5lOuW6jd3U1WFG9NMZTlRXQJgjBj4ZgPmyjFxbLepQK-zb6aMC9e_hoMBkOdeHVnZ28Rofbt-QItdZ5od6AW7uO35aM_AV0lqio
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+the+Phosphate+Binder+Sevelamer+Carbonate+on+the+Bioavailability+of+Enarodustat%2C+an+Oral+Erythropoiesis+Stimulating+Agent&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Pai%2C+Sudhakar+M&rft.au=Yamada%2C+Hiroyuki&rft.date=2024-01-01&rft.eissn=2160-7648&rft.volume=13&rft.issue=1&rft.spage=111&rft_id=info:doi/10.1002%2Fcpdd.1336&rft_id=info%3Apmid%2F37975611&rft.externalDocID=37975611
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon